NCT06274489 - A Study to Evaluate Setanaxib in Patients With Alport Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

June 24, 2025

Study Completion Date

June 25, 2025

Conditions

Alport Syndrome

Interventions

DRUG

Setanaxib

Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4. It is a low molecular weight organic molecule and a member of the pyrazolopyridine dione chemical class.

DRUG

Placebo

Matching film-coated placebo tablets, containing only excipients

Trial Locations (17)

1090

Medizinische Universitaet Wien, Vienna

14004

Hospital Universitario Reina Sofia, Córdoba

18014

Hospital Universitario Virgen de las Nieves, Granada

28040

Hospital Fundacion Jimenez Diaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

75015

AP-HP Hopital Necker-Enfants Malades, Paris

Unknown

Fakultni Nemocnice Hradec Kralove, Hradec Králové

Fakultni Nemocnice Olomouc, Olomouc

Institut Klinicke a Experimentalni Mediciny, Prague

Vseobecna Fakultni Nemocnice v Praze, Prague

Hospital Universitario Vall d'Hebron, Barcelona

Nottingham City Hospital, Nottingham

08025

Fundacio Puigvert, Barcelona

08036

Hospital Clinic Barcelona, Barcelona

NW3 2QG

Royal Free London NHS Foundation Trust, London

WC1N 3JH

Great Ormond Street Hospital for Children, London

M13 9WL

Royal Manchester Children's Hospital, Manchester